Table 2 Patient Therapy (n = 236)
Therapy | n (%) |
|---|---|
Anti-Endocrine Therapy = 165 (69.9) | |
 Tamoxifen | 75 (31.7) |
 Anastrozole (Arimidex) | 45 (19) |
 Exemestane (Aromasin) | 8 (3.3) |
 Letrozole (Femara) | 32 (13.5) |
 Goserelin (Zoladex) | 4 (1.6) |
 Aromatase Inhibitors | 1 (0.4) |
HER2 Therapy = 67 (28.4) | |
 Trastuzumab (Herceptin) | 66 (27.9) |
 Lapatinib (Tyverb) | 1 (0.4) |
Chemotherapy | 194 (82.2) |
 AC: Adriamycin (Doxorubicin), Cyclophosphamide | 49 (20.7) |
 Anthracycline | 1 (0.4) |
 Docetaxel (Taxotere) | 19 (8.0) |
 TAC: Docetaxel (Taxotere), Adriamycin (Doxorubicin) and Cyclophosphamide | 22 (9.3) |
 TC: Docetaxel (Taxotere) and Cyclophosphamide | 1 (0.4) |
 TCH: Docetaxel (Taxotere), Carboplatin and Trastuzumab | 9 (3.8) |
 EC: Epirubicin and Cyclophosphamide | 3 (1.2) |
 FEC: 5-Fluorouracil, Epirubicin and Cyclophosphamide | 45 (19.0) |
 Paclitaxel (Taxol)/Taxane | 36 (15.2) |
 FAC (or CAF): 5-Fluorouracil, Doxorubicin and Cyclophosphamide | 4 (1.6) |
 Capecitabine (Xeloda) | 3 (1.2) |
 5-Fluorouracil | 1 (0.4) |
 Carboplatin | 1 (0.4) |
Unknown | 46 (19.4) |